Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Cetera Investment Advisers

Cetera Investment Advisers grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 8.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,013 shares of the biotechnology company’s stock after acquiring an additional 1,022 shares during the quarter. Cetera Investment Advisers’ holdings in Sarepta Therapeutics were worth $2,056,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after purchasing an additional 243,180 shares during the last quarter. Capital International Investors increased its position in shares of Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after purchasing an additional 76,032 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Sarepta Therapeutics by 5.6% during the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after purchasing an additional 217,810 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after purchasing an additional 37,940 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. BMO Capital Markets lifted their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. UBS Group lifted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Robert W. Baird lifted their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. Finally, Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and decreased their price objective for the company from $185.00 to $179.00 in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $185.47.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $124.51 on Monday. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $173.25. The stock has a 50 day moving average of $130.19 and a two-hundred day moving average of $132.51. The stock has a market cap of $11.77 billion, a P/E ratio of 1,131.91 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same quarter in the previous year, the business earned ($0.27) earnings per share. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Michael Andrew Chambers bought 37,038 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.